Who published this market news?

TradingView published this market news item.

Arcutis appoints Christopher Peetz to its board as Class III director

Arcutis appointed Christopher Peetz to its Board as a Class III director, effective July 15, 2026.Original SEC Filing: Arcutis Biotherapeutics, Inc. [ ARQT ] - 8-K - Jul. 16, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Pl…

Arcutis appointed Christopher Peetz to its Board as a Class III director, effective July 15, 2026.

IndividualChristopher Peetz

RoleClass III Director (non-employee)

Type of ChangeAppointed

Effective DateJuly 15, 2026

ReasonBoard increased authorized directors from nine to ten and appointed Mr. Peetz

Replacement InfoNot disclosed

Background DetailsCo‑founder and CEO of Mirum Pharmaceuticals since Mar 2019; prior CEO roles at Flashlight Therapeutics and Tobira; CFO/head of corporate development at Tobira; past roles at Jennerex, Onyx, LaSalle Corporate Finance; MBA Stanford; B.S.B.A. Washington University

Board/Committee Role ChangesHas not been appointed to any committee

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.